• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to: Upadacitinib for the management of overlapping psoriasis and atopic dermatitis: a case series.

作者信息

Foggia Luciano, Potestio Luca, Patruno Cataldo, di Vico Francesca, Napolitano Maddalena

机构信息

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.

出版信息

Int J Dermatol. 2025 Jan;64(1):218. doi: 10.1111/ijd.17594. Epub 2024 Dec 4.

DOI:10.1111/ijd.17594
PMID:39628371
Abstract
摘要

相似文献

1
Reply to: Upadacitinib for the management of overlapping psoriasis and atopic dermatitis: a case series.回复：乌帕替尼治疗重叠性银屑病和特应性皮炎：病例系列
Int J Dermatol. 2025 Jan;64(1):218. doi: 10.1111/ijd.17594. Epub 2024 Dec 4.
2
Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series.乌帕替尼治疗银屑病合并特应性皮炎：病例系列
J Dermatolog Treat. 2023 Dec;34(1):2183729. doi: 10.1080/09546634.2023.2183729.
3
Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report.达必妥诱发特应性皮炎患者发生银屑病，使用乌帕替尼成功治疗：一例报告
SAGE Open Med Case Rep. 2025 Feb 3;13:2050313X251317811. doi: 10.1177/2050313X251317811. eCollection 2025.
4
Upadacitinib for the management of overlapping psoriasis and atopic dermatitis: a case series.乌帕替尼用于重叠性银屑病和特应性皮炎的管理：病例系列
Int J Dermatol. 2025 Mar;64(3):623-625. doi: 10.1111/ijd.17512. Epub 2024 Oct 6.
5
Phenotypic switch from atopic dermatitis to psoriasis during treatment with upadacitinib.在使用乌帕替尼治疗期间，特应性皮炎向银屑病的表型转换。
Clin Exp Dermatol. 2022 May;47(5):986-987. doi: 10.1111/ced.15104. Epub 2022 Feb 2.
6
Upadacitinib for moderate to severe atopic dermatitis.巴瑞替尼治疗中重度特应性皮炎。
Immunotherapy. 2023 Aug;15(11):799-808. doi: 10.2217/imt-2023-0037. Epub 2023 May 17.
7
Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children.儿童中重度特应性皮炎患者接受度普利尤单抗治疗后出现银屑病样皮炎。
Pediatr Dermatol. 2021 Nov;38(6):1500-1505. doi: 10.1111/pde.14820. Epub 2021 Oct 14.
8
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.度普利尤单抗联合局部皮质类固醇治疗青少年和成人中重度特应性皮炎（AD Up）的安全性和有效性：一项随机、双盲、安慰剂对照、3 期临床试验的结果。
Lancet. 2021 Jun 5;397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4. Epub 2021 May 21.
9
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).度普利尤单抗治疗成人和青少年中重度特应性皮炎的疗效和生活质量：两项 III 期随机临床试验（Measure Up 1 和 Measure Up 2）的 52 周结果。
Am J Clin Dermatol. 2024 May;25(3):485-496. doi: 10.1007/s40257-024-00853-4. Epub 2024 Mar 25.
10
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.阿布昔替尼、特利鲁单抗和乌帕替尼治疗中重度特应性皮炎。
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.

引用本文的文献

1
Psoriasiform Dermatitis: From Pathogenesis to New Therapeutic Opportunities.银屑病样皮炎：从发病机制到新的治疗机遇
Life (Basel). 2025 Jun 27;15(7):1026. doi: 10.3390/life15071026.